Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUTASTERIDE vs FINASTERIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of type II and type I 5α-reductase isoenzymes, blocking conversion of testosterone to dihydrotestosterone (DHT) in prostate, hair follicles, and other tissues.
Finasteride is a competitive 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), thereby reducing DHT levels in serum and prostate tissue.
FDA: Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate,FDA: Reduce risk of acute urinary retention,FDA: Reduce need for BPH-related surgery,Off-label: Male androgenetic alopecia
Benign prostatic hyperplasia (BPH),Male pattern baldness (androgenetic alopecia)
0.5 mg orally once daily.
1 mg orally once daily for androgenetic alopecia; 5 mg orally once daily for benign prostatic hyperplasia.
Terminal half-life approximately 3-4 weeks (21-35 days) in young adults; 5-6 weeks in elderly; supports once-daily dosing due to slow elimination.
Terminal elimination half-life is approximately 6-8 hours (range 4-12 hours) in young adults; prolonged to ~8 hours in elderly due to reduced clearance; clinical effect on DHT suppression persists for 24 hours post-dose.
Extensively metabolized in liver via CYP3A4 and CYP1A2; minor metabolism by CYP2C8, CYP2C9, CYP2C19, and CYP2D6.
Metabolized primarily via CYP3A4 in the liver; two inactive metabolites (t-butyl side chain oxidation and glucuronide conjugate).
Primarily fecal (70%) as metabolites; renal excretion accounts for <5% unchanged drug.
Renal (39% as metabolites, <0.1% as unchanged drug); fecal (57% as metabolites); biliary elimination contributes to fecal route.
>99% bound to albumin and alpha-1 acid glycoprotein; high affinity.
Approximately 93% bound to plasma proteins (primarily albumin and to a lesser extent alpha-1-acid glycoprotein).
Approximately 300-500 L (3-5 L/kg), indicating extensive tissue distribution, particularly to prostate and seminal vesicles.
Volume of distribution = 76 L (approximately 1.0-1.1 L/kg), indicating extensive tissue distribution; crosses blood-brain barrier and partitions into seminal fluid.
Oral: Approximately 60% (range 40-80%) with food; not administered parenterally.
Oral bioavailability is approximately 63% (range 50-80%) due to incomplete absorption and first-pass metabolism; food does not significantly affect bioavailability.
No dose adjustment required for renal impairment (including dialysis).
No dose adjustment required for any level of renal impairment including end-stage renal disease.
Contraindicated in Child-Pugh Class C; use with caution in mild to moderate impairment (Child-Pugh A/B) with no specific dose adjustment established.
No formal studies in hepatic impairment. Caution advised; use not recommended in severe hepatic impairment due to potential accumulation. No specific Child-Pugh based dose recommendations.
Not indicated in pediatric patients; safety and efficacy not established.
Not indicated in pediatric patients. Safety and efficacy not established. Avoid use in children.
No specific dose adjustment required; monitor for adverse effects (e.g., dizziness, orthostatic hypotension) due to age-related comorbidities.
No age-related dose adjustment necessary. Monitor for adverse effects (e.g., sexual dysfunction, mood changes) due to potential increased sensitivity.
No FDA black box warning.
No FDA black box warning.
Risk of high-grade prostate cancer in men aged 50-79 with elevated PSA and previous negative biopsy (see PLCO trial),Increased risk of sexual adverse events (impotence, decreased libido, ejaculation disorders) that may persist after discontinuation,Elevated PSA levels: use caution when interpreting PSA values; establish new baseline after 6 months of treatment
Risk of high-grade prostate cancer (decreased PSA levels may mask detection),Sexual adverse effects (e.g., decreased libido, erectile dysfunction, ejaculatory disorder) may persist after discontinuation,Increased risk of mood disturbances including depression and suicidal ideation,Not indicated for use in women or children; avoid handling crushed tablets during pregnancy due to risk to male fetus
Women of childbearing potential (pregnancy category X; risk of fetal harm due to inhibition of 5α-reductase),History of hypersensitivity to dutasteride or other 5α-reductase inhibitors,Pediatric patients
Pregnancy (category X; risk of hypospadias in male fetuses),Known hypersensitivity to finasteride or any component of the formulation
No clinically significant food interactions. May be taken with or without food. Grapefruit juice does not affect dutasteride levels to a clinically relevant extent.
No significant food interactions reported; finasteride may be taken with or without food. Avoid excessive alcohol consumption as it may worsen BPH symptoms or liver function.
Dutasteride is contraindicated in pregnancy. It is a 5α-reductase inhibitor that can inhibit the conversion of testosterone to dihydrotestosterone (DHT), potentially causing abnormal development of external genitalia in male fetuses. Risk extends throughout all trimesters due to potential disruption of androgen-mediated development in male fetuses during the first trimester and cumulative effects from drug accumulation in adipose tissue. No adequate human studies exist; animal studies show teratogenicity in male offspring at clinically relevant doses.
Contraindicated in pregnancy. Finasteride inhibits conversion of testosterone to dihydrotestosterone, which is critical for male fetal external genitalia development. Risk of hypospadias and other urogenital malformations if exposed in utero, particularly during first trimester. Pregnancy category X.
No data on dutasteride in human milk. M/P ratio unknown. Dutasteride is highly lipophilic and likely excreted in breast milk. Because of potential adverse effects on the nursing infant (e.g., interference with androgen-mediated development in male infants), breastfeeding is contraindicated during therapy and for at least 6 months after the last dose due to long half-life (approximately 5 weeks).
Not recommended. Finasteride is excreted in human milk; M/P ratio not reported. Risk to nursing infant unknown, but potential for adverse effects on male infant genitalia. Use contraindicated during breastfeeding.
No dose adjustment studies in pregnancy because dutasteride is contraindicated. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) could affect dutasteride levels, but no adjustments are recommended as drug should not be used. If inadvertently used, discontinue immediately and monitor for adverse effects.
No dose adjustments applicable as finasteride is contraindicated in pregnancy. No pharmacokinetic studies in pregnant women due to ethical concerns.
Monitor PSA levels cautiously, as dutasteride reduces serum PSA by approximately 50% after 6 months; double the PSA value for comparison to untreated men. Do not handle crushed or broken capsules if pregnant or planning pregnancy, as absorption through skin may cause fetal harm. Assess for signs of high-grade prostate cancer before initiating therapy, as dutasteride may increase the risk of Gleason 8-10 tumors. Onset of symptom relief may take 3-6 months; do not discontinue prematurely. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) as they increase dutasteride exposure.
Finasteride inhibits 5α-reductase type II, reducing conversion of testosterone to DHT. Onset of effect in benign prostatic hyperplasia (BPH) requires 6-12 months; for androgenetic alopecia, 3-6 months. Serum PSA levels decrease by approximately 50% after 6 months; multiply PSA by 2 when interpreting. Avoid handling crushed or broken tablets if pregnant or planning to become pregnant due to risk of fetal genital abnormalities. Use with caution in hepatic impairment; contraindicated in women of childbearing potential, children, and patients with hypersensitivity to 5α-reductase inhibitors.
Take exactly as prescribed; do not stop or change dose without consulting your doctor.,Swallow the capsule whole; do not chew or open it.,It may take 3 to 6 months to see improvement in symptoms.,Avoid handling leaking or crushed capsules if you are a woman who is or may become pregnant; wash area immediately with soap and water if skin contact occurs.,Do not donate blood for at least 6 months after your last dose to prevent exposure to a pregnant woman.,Report any breast lumps, pain, or nipple discharge promptly.,You will need regular blood tests for PSA level monitoring; inform your doctor that you are taking dutasteride.,Dutasteride can decrease sperm count and may affect fertility; discuss this with your doctor if planning to father a child.
Take finasteride exactly as prescribed, once daily with or without food.,It may take 3-6 months for hair regrowth or improvement in urinary symptoms; continue therapy as directed even if no immediate benefit is noted.,Report any breast tenderness, enlargement, or lumps; also report any new onset of sexual dysfunction (e.g., decreased libido, erectile dysfunction, ejaculation disorder).,Do not donate blood while taking finasteride and for at least 1 month after stopping, to prevent exposure to a pregnant female.,Women who are pregnant or may become pregnant should not handle crushed or broken tablets due to risk of harm to male fetus.,Serum PSA levels will decrease; inform your healthcare provider that you take finasteride before any PSA test.,Store at room temperature (20-25°C) in a dry place, away from light and moisture.
"Dutasteride, a 5α-reductase inhibitor, may inhibit cytochrome P450 enzymes, particularly CYP3A4, which is involved in the metabolism of sulfisoxazole. This inhibition can lead to decreased clearance of sulfisoxazole, resulting in elevated plasma concentrations. Increased sulfisoxazole levels may potentiate its adverse effects, including hypersensitivity reactions, crystalluria, and hematologic toxicity such as agranulocytosis."
"Concomitant use of dutasteride, a 5α-reductase inhibitor, with nelfinavir, a protease inhibitor and potent CYP3A4 inhibitor, is predicted to increase the serum concentration of nelfinavir. This occurs because dutasteride may inhibit the metabolism of nelfinavir via competition for CYP3A4, leading to elevated nelfinavir levels and an increased risk of adverse effects such as gastrointestinal disturbances, hepatotoxicity, and metabolic complications. Clinical monitoring for toxicity and dose adjustments are warranted."
"Dutasteride, a 5α-reductase inhibitor, is metabolized primarily by CYP3A4 and to a lesser extent by CYP2D6. Itraconazole is a potent inhibitor of CYP3A4 and also inhibits P-glycoprotein. Coadministration leads to significantly increased serum concentrations of dutasteride, raising the risk of adverse effects such as gynecomastia, sexual dysfunction, and depression. The effect on itraconazole levels is minimal and clinically irrelevant."
"Finasteride, a 5α-reductase inhibitor used for benign prostatic hyperplasia, may inhibit cytochrome P450 3A4 (CYP3A4) isoenzymes. Cyclosporine is primarily metabolized by CYP3A4. Coadministration can lead to reduced cyclosporine clearance, elevated blood concentrations, and increased risk of nephrotoxicity, hypertension, and neurotoxicity."
"Finasteride, a 5α-reductase inhibitor used for benign prostatic hyperplasia, may weakly inhibit CYP3A4, the primary enzyme responsible for sildenafil metabolism. This can lead to a modest reduction in sildenafil clearance, increasing systemic exposure and potentially enhancing both therapeutic effects and adverse events such as headache, flushing, dyspepsia, and hypotension. Clinically, this interaction is generally mild but may require dose adjustment in patients predisposed to sildenafil side effects."
"Finasteride, a 5α-reductase inhibitor, may inhibit CYP3A4-mediated metabolism of netupitant, a neurokinin-1 receptor antagonist primarily metabolized by CYP3A4. This can lead to increased netupitant plasma concentrations, potentially enhancing its adverse effects such as headache, fatigue, or dizziness. Clinically, the combination may require dose adjustment or close monitoring for netupitant toxicity."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUTASTERIDE vs FINASTERIDE, answered by our medical review team.
DUTASTERIDE is a 5-alpha Reductase Inhibitor that works by Competitive inhibitor of type II and type I 5α-reductase isoenzymes, blocking conversion of testosterone to dihydrotestosterone (DHT) in prostate, hair follicles, and other tissues.. FINASTERIDE is a 5-alpha Reductase Inhibitor that works by Finasteride is a competitive 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), thereby reducing DHT levels in serum and prostate tissue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUTASTERIDE and FINASTERIDE depend on the specific clinical indication. These are both 5-alpha Reductase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUTASTERIDE is: 0.5 mg orally once daily.. The standard adult dose of FINASTERIDE is: 1 mg orally once daily for androgenetic alopecia; 5 mg orally once daily for benign prostatic hyperplasia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUTASTERIDE and FINASTERIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUTASTERIDE is classified as Category D/X. Dutasteride is contraindicated in pregnancy. It is a 5α-reductase inhibitor that can inhibit the conversion of testosterone to dihydrotestosterone (DHT), potentially causing abnorm. FINASTERIDE is classified as Category D/X. Contraindicated in pregnancy. Finasteride inhibits conversion of testosterone to dihydrotestosterone, which is critical for male fetal external genitalia development. Risk of hypos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.